Cannabinoids in late‐onset Alzheimer’s disease

Authors:

AIA Ahmed, MA van der Marck, GAH van den Elsen, MGM Olde Rikkert


Published in Clinical Pharmacology & Therapeutics

8 March 2015

 

Abstract

Given the lack of effective treatments for late-onset Alzheimer’s disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing interest in the medicinal uses of cannabinoids, the bioactive components of the cannabis plant, including the treatment of LOAD and other physical conditions that are common in older people. Several in vitro and in vivo studies have demonstrated that cannabinoids can reduce oxidative stress, neuroinflammation, and the formation of amyloid plaques and neurofibrillary tangles, the key hallmarks of LOAD. In addition, in population-based studies, cannabinoids reduced dementia-related symptoms (e.g., behavioral disturbances). The current article provides an overview of the potential of cannabinoids in the treatment of LOAD and related neuropsychiatric symptoms in older people. We also discuss the efficacy, safety, and pharmacokinetics of cannabinoid-based drugs in older people with dementia.

 

DOI: 10.1002/cpt.117

PAYWALL

Citation:

Ahmed A, Marck MVD, Elsen GVD, Rikkert MO. Cannabinoids in late-onset Alzheimers disease. Clinical Pharmacology & Therapeutics. 2015;97(6):597-606. doi:10.1002/cpt.117.